Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Soft Tissues: Inflammatory myofibroblastic tumor with t(2;11)(p23;p15) CARS/ALK

Written2003-08Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C470-C476,C478-C479,C490-C496,C498-C499 CONNECTIVE & SOFT TISSUE
ICD-Morpho 8825/1 Inflammatory myofibroblastic tumour
Atlas_Id 5213
Phylum Soft Tissues::Inflammatory myofibroblastic tumor

Clinics and Pathology

Disease Inflammatory myofibroblastic tumors
Clinics rare soft tissue tumour found in children and young adults
Pathology spindle cell proliferation with myofibroblastic differenciation and an inflammatory infiltrate
Cytogenetics The translocation was found complex: t(2;11;2)(p23;p15;q31)
Prognosis low malignant potential and good prognosis

Genes involved and Proteins

Gene NameALK (anaplastic lymphoma receptor tyrosine kinase)
Location 2p23.2
Protein 1620 amino acids; 177 kDa; glycoprotein (200 kDa mature protein) ; membrane associated tyrosine kinase receptor

Gene NameCARS (cysteinyj-tRNA synthetase)
Location 11p15.4
Protein 748 amino acids, 85 kDa. Forms homodimers

Result of the chromosomal anomaly

Hybrid Gene
Description 5' CARS - 3' ALK
Fusion Protein
Description 606 N-term amino acid from CARS, fused to the 562 C-term amino acids from ALK (i.e. the entire cytoplasmic portion of ALK with the tyrosine kinase domain).
  

Bibliography

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P
Genes, chromosomes & cancer. 2002 ; 34 (4) : 354-362.
PMID 12112524
 
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.
Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ
Cancer research. 1999 ; 59 (12) : 2776-2780.
PMID 10383129
 
Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.
Ladanyi M
The American journal of pathology. 2000 ; 157 (2) : 341-345.
PMID 10934137
 
Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, Zuppan C, Bridge JA
Genes, chromosomes & cancer. 2003 ; 37 (1) : 98-105.
PMID 12661011
 

Citation

This paper should be referenced as such :
Huret, JL
t(2;11)(p23;p15)
Atlas Genet Cytogenet Oncol Haematol. 2003;7(4):290-290.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Tumors/t0211p23p15ID5213.html


Other genes implicated (Data extracted from papers in the Atlas) [ 2 ]

Genes ALK CARS

Translocations implicated (Data extracted from papers in the Atlas)

 t(2;11)(p23;p15) CARS/ALK

External links

Mitelman database t(2;11)(p23;p15) CARS/ALK [Case List]    t(2;11)(p23;p15) CARS/ALK [Association List] Mitelman database (CGAP - NCBI)
arrayMap Topo ( C47,C49) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
COSMIC_fusionCARS (11p15.4) ALK (2p23.2)    [fusion437] [fusion438] [fusion753]
Mitelman databaseCARS/ALK[MCList]    CARS (11p15.4) ALK (2p23.2)   
Mitelman databaseCARS/ALK[MCList]    CARS (11p15.4) ALK (2p23.2)   t(2;11)(p23;p15)
TICdbCARS/ALK    CARS (11p15.4) ALK (2p23.2)
 
Disease databaseSoft Tissues: Inflammatory myofibroblastic tumor with t(2;11)(p23;p15) CARS/ALK
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 15:11:37 CET 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.